As the CGT space grows, making therapies available to more patients will require an all-encompassing approach to improving efficiency to lower manufacturing costs. New seed train technologies can not only improve viral vector manufacturing but has applications for other types of adherent production that may be leveraged for a broad range of next-gen therapeutics.